- Home
- EXAS
as 10-24-2025 3:50pm EST
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | MADISON |
| Market Cap: | 11.0B | IPO Year: | N/A |
| Target Price: | $69.24 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $38.81 - $72.83 | Next Earning Date: | 11-03-2025 |
| Revenue: | $2,939,949,000 | Revenue Growth: | 12.55% |
| Revenue Growth (this year): | 16.68% | Revenue Growth (next year): | 12.12% |
Stock Insider Trading Activity of Exact Sciences Corporation (EXAS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Herriott James | EXAS | SVP, General Counsel & Sec | Oct 9 '25 | Sell | $60.00 | 1,500 | $90,000.00 | 14,085 | |
| Doyle James Edward | EXAS | Director | Oct 9 '25 | Sell | $60.00 | 2,000 | $120,000.00 | 57,962 | |
| Doyle James Edward | EXAS | N/A | Aug 13 '25 | Sell | $42.02 | 1,485 | $62,399.70 | 57,962 |
Latest Exact Sciences Corporation News
EXAS Breaking Stock News: Dive into EXAS Ticker-Specific Updates for Smart Investing
Zacks
16 days ago
5 Growth Stocks to Strengthen Your Portfolio in Q4 After a Fabulous Q3
Simply Wall St.
22 days ago
How Recent Developments Are Reshaping the Story for Exact Sciences
Zacks
24 days ago
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock
Zacks
25 days ago
Exact Sciences (EXAS) Just Flashed Golden Cross Signal: Do You Buy?
Zacks
a month ago
Why Exact Sciences (EXAS) is a Top Momentum Stock for the Long-Term
Business Wire
a month ago
Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test
Insider Monkey
a month ago
Exact Sciences, Healthmine Partner to Boost Cologuard Screening Rates via Health Plan Incentives
Business Wire
a month ago
Healthmine and Exact Sciences Partner to Combine At-Home CRC Screening with Health Plan Incentives to Boost Preventive Care
Compare EXAS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXAS Exact Sciences Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.